News AZ immunotherapy gets FDA boost in early lung cancer Imfinzi given Breakthrough Therapy designation from the FDA.
News ASCO round up: Zytiga shines in frontline prostate role, Lox... While ASCO often showcases the benefits of new cancer therapies, it was a well-established drug that proved to be a talking point at this year’s conference in Chicago.
News Major UK market breakthrough for Keytruda in lung cancer But funding will last only two years on CDF.
News AZ highlights data from next-gen oncology drugs at ASCO Tesara and Takeda among other companies to publish data.
News The week that turned the cancer immunotherapy market on its ... Contrasting fortunes for Roche and AZ in a week of drama.
News Takeda gets return on Ariad buy with approval of brigatinib But Japanese pharma bracing for US patent expiry on blockbuster Velcade
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
